Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions HER2-positive Breast Cancer
Phase PHASE1
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [18F]FMISO PET/MRI imaging — \[18F\]FMISO PET/MRI imaging

Primary Outcomes

  • Baseline measure of PET standardized uptake value (SUV). (Baseline)
  • Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI. (Baseline)
  • Baseline measure of signal enhancement ratio (SER) from MRI. (Baseline)
  • Changes in SER from MRI (Baseline through 6 months)
  • Changes in ADC from MRI (Baseline through 6 months)
  • Changes in SUV from PET (Baseline through 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-03-25
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Jonathan McConathy, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Anna Sorace, PhD
205-934-3116
asorace@uabmc.edu
Sebastian Eady
2059962636
smeady@uabmc.edu
April Riddle, BSRT
205-934-6504
ariddle@uabmc.edu
The University of Alabama at Birmingham
Interventions
  • Drug: [18F]FMISO PET/MRI imaging — \[18F\]FMISO PET/MRI imaging
Study Locations (1 sites)
The University of Alabama at Birmingham, Birmingham, Alabama 35249 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients must be ≥ 18 years old and ≤ 75 years old 2. HER2+ breast cancer determined on primary tumor by a local pathology laboratory and defined as IHC score 3+ and/or positive by ISH (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Only one positive result is required for eligibility 3. Locally advanced stage II-III HER2+ breast cancer patients eligible for neoadjuvant therapy who are naïve to beginning treatment 4. Estimated life expectancy of greater than one year 5. Patients must have one lesion with RECIST measurable disease (great than 1 cm in diameter) Exclusion Criteria: 1. Inability to provide informed consent F 2. Weight over 350 lbs., due to the scanner bore size 3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum β-hCG pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 48 hours of each PET imaging study. 4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) 5. Unable to lie still on the imaging table for one (1) hour 6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)
Conditions Breast Cancer
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This research trial establishes a breast tumor tissue repository from core biopsies. Collecting breast tissue from core biopsies may allow doctors to learn more about the biology of breast cancer and to analyze proteins, genes, and other components of tumor cells. It may also allow doctors to conduct future studies to help understand how breast cancer grows and how it responds to different types of therapy. This will help doctors develop better breast cancer therapies and better tests to help make treatment decisions.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: cytology specimen collection procedure — Correlative studies

Primary Outcomes

  • Development of a baseline and serial breast cancer core biopsy repository within the USC/Norris Comprehensive Cancer Center Women's Cancer Program (Up to 10 years)
  • Development and maintenance of a secure clinical database of relevant demographic, clinical, pathologic, and longitudinal outcome characteristics of the samples to be banked (Up to 10 years)
  • Development of an efficient process for the distribution of de-identified samples from the bank to researchers with IRB-approved protocols or exemptions for the study of breast cancer-related questions (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-11-14
Completion: 2027-11-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Evanthia Roussos-Torres, M.D. (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Zeno Ashai
323-865-0463
zeno.ashai@med.usc.edu
Ameria Casillas-Lopez
323-865-0804
America.Casillas-Lopez@med.usc.edu
USC Norris Comprehensive Cancer Center
Julie Lang, M.D.
USC Norris Comprehensive Cancer Center
Interventions
  • Other: cytology specimen collection procedure — Correlative studies
Study Locations (1 sites)
USC Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Known or suspected breast cancer * Known or suspected metastatic solid tumor that originated in the breast per the patient's medical history Exclusion Criteria: * Inability to sign informed consent * Known bleeding disorder * Use of anticoagulant medications (heparin, warfarin, etc.) within one week prior to biopsy * Use of antiplatelet medications (aspirin, clopidogrel, etc.) within one week prior to biopsy
Conditions Early-stage Breast Cancer, Estrogen-rece...
Phase PHASE2
Enrollment 112
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: Prospective data and sample collection — Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
  • Drug: Ketorolac 10 Mg Oral Tablet — Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
  • Drug: Pregabalin 75mg — Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
  • Drug: Omeprazole 20mg Capsule — Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery

Primary Outcomes

  • To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac (Up to 24 hours after surgery)
  • To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin (Up to 24 hours after surgery)
  • Change in biomarkers of metastasis at surgery from baseline (At surgery)
  • Change in tumoral immune cells recruitment at surgery from baseline (At surgery)
  • Change in tumoral neurogenesis at surgery from baseline (At surgery)
  • Change in tumoral neurotransmitters level at surgery from baseline (At surgery)
  • Change in Peripheral Blood Mononuclear Cells at surgery from baseline (At surgery)
  • Change in systemic neuro-inflammatory mediators at surgery from baseline (At surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-12
Completion: 2027-10
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jules Bordet Institute
Collaborators: KU Leuven
Principal Investigators:
  • Christine Desmedt, PhD (STUDY_CHAIR) - KU Leuven
  • Imane Bachir, MD (STUDY_CHAIR) - Jules Bordet Institute
Contact Information
Study Contact:
Imane Bachir, MD
+3225413601
imane.bachir@bordet.be
Marion Maetens, PhD
+3216321194
marion.maetens@kuleuven.be
Imane Bachir, MD
+322541
imane.bachir@hubruxelles.be
Institut Jules Bordet
Interventions
  • Procedure: Prospective data and sample collection — Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
  • Drug: Ketorolac 10 Mg Oral Tablet — Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
  • Drug: Pregabalin 75mg — Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
  • Drug: Omeprazole 20mg Capsule — Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
Study Locations (1 sites)
Institut Jules Bordet, Brussels, 1170 Belgium
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria in order to be eligible for this study: 1. Age ≥ 18 years and ≤ 70 years old 2. Female 3. Weight ≥ 35 kg 4. Histological diagnosis of invasive breast adenocarcinoma that is estrogen receptor positive as per the updated American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) guidelines according to local testing with ER-positive is defined as having an immunohistochemistry (IHC) of 1% or more and/or Allred score of 3 or more 5. Tumour size ≥ 1.5 cm, determined by diagnostic ultrasound or MRI/CT scan. 6. Stage I, II or III disease (non-metastatic) 7. In case of multifocal, multicentric unilateral or bilateral breast: Adenocarcinoma tumours are allowed provided that all foci are ER+ according to local testing 8. Subject scheduled for a primary breast cancer surgery 9. Subject is willing to provide plasma/blood and tumour samples for translational research. 10. Subject is willing to provide tissue from a newly obtained core or excisional biopsy of the tumour that should be evaluable for central histological characterization and future molecular testing 11. Subject is willing to take omeprazole and has no contraindication to omeprazole. 12. Have an HEMSTOP score\<2 and conventional coagulation screening test within normal limits such as activated partial thromboplastin time (21.6\< aPTT \>28.7), international normalised ratio (1.31\<INR) and platelet count (\>100.10³/ml) 13. Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least one months after the last administration of study treatment. 14. Negative serum pregnancy test for women of childbearing potential (within 30 days before start of treatment) 15. Subject is willing and able to provide written informed consent for the trial Exclusion Criteria: Subjects meeting one of the following criteria are not eligible for this study: 1. Subject planned for intraoperative radiotherapy 2. Subject planned for immediate reconstruction 3. Neoadjuvant BC therapy 4. Allergy to any NSAID or gabapentinoïd 5. Known hypersensitivity reactions to the investigational treatments, or any excipients or auxiliary medicinal products or concomitant medications. Hypersensitive to peanut or soya (related to propofol contraindications) 6. Current use of the antidiabetic agent thiazolidinedione (related to interaction with pregabalin), lithium salts, probenecid, pentoxifylline or intensive diuretic therapy. 7. Current NSAID (\> twice a week the year prior to diagnosis) or pregabalin use 8. Previous malignant pathology within 5 years prior to inclusion or currently undergoing maintenance therapy. Exceptions include basal cell carcinoma or squamous cell carcinoma of the skin that have undergone potentially curative therapy or in situ cervical cancer. 9. Active or history of peptic ulcer disease or gastro-intestinal bleeding or perforation 10. Pregnancy or lactating women 11. Chronic inflammatory disease as rheumatoid arthritis, uncontrolled asthma, chronic heart failure, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory myopathies (e.g., idiopathic polymyositis, dermatomyositis, inclusion body myositis), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), McArdle's disease, multiple sclerosis, lupus, chronic inflammatory demyelinating polyneuropathy, psoriasis, autoimmune thyroiditis as Graves' disease or Hashimoto's thyroiditis (unless previous surgical ablation), myasthenia gravis, vasculitis. 12. Complete or partial nasal polyposis syndrome, Quincke's oedema, bronchospasm, asthma 13. Known chronic infectious disease as active hepatitis B (defined as positive serology for Ac anti-HBc and IgM anti HBc OR Ac anti HBc and Ag HBs), active hepatitis C (defined as positive serology for anti-VHC and positive PCR-VHC) or active tuberculosis (included under treatment) 14. Uncontrolled HIV infection (defined as detectable viral loads by standard clinical assays) or controlled HIV infection (defined undetectable HIV viral loads by standard clinical assays) treated by one of following drugs: Nelfinavir, Atazanavir or Saquinavir (related to interaction with omeprazole). 15. Infection currently treated with one of the following drugs: posaconazole, voriconazole, ketoconazole and rifampicin, unless discontinuation of treatment is planned at least 10 days prior to the start of study treatment AND with complete resolution according to expert opinion (related to interaction with omeprazole) 16. Inadequate liver function (defined as total serum bilirubin ≥ 2 x upper limit of normal (ULN\<1.2 mg/dl) - unless documented Gilbert syndrome- AND Alanine Aminotransferase (ALT) ≥ 2 x ULN (ULN \<32 UI/l and ULN \<33 UI/l, respectively) AND Alkaline phosphatase (ALP) ≥ 2.5 x ULN (ULN=104 UI/l)) 17. Cirrhosis or severe hepatitis. 18. Renal impairment (defined as GFR\<90ml/min/1.73m² or serum creatinine \> 442 μmol/l or \> 5 mg/dL) or single kidney or previous renal surgery 19. Subject with history of (severe) renal toxicity with an NSAID 20. Subject with a recent history of operations associated with a high risk of bleeding 21. Previous, ongoing or suspected cardiovascular disease defined as history of ischemic heart disease or heart failure or uncontrolled high blood pressure (Systolic ≥160mmHg and/or diastolic ≥100mmHg) or peripheral arterial disease or cerebrovascular disease 22. Subject with a recent history of surgery associated with a high risk of bleeding 23. Hemostasis disorder as haemophilia, Von Willebrand disease, constitutional thrombopathies or thrombocytopenia (defined as platelet count \< 100 000/mm³), current /planned anticoagulant or anti-platelet therapy. 24. Inadequate bone marrow function (defined as absolute neutrophil count \<1000/μL and platelet count \<100'000/μL) 25. Systemic immunosuppressive treatment (defined as systemic corticotherapy or anti-rejection treatment or interferon therapy) within the 2-years prior diagnosis 26. Psychiatric disease or antipsychotic/ antidepressant use 27. Epilepsy or any current anti-epileptic drug use 28. Obstructive sleep apnea 29. ASA≥3
Conditions Breast Neoplasms
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug. Results from the phase I safety, tolerability and pharmacokinetic trial of ARX788 single drug in Chinese patients with advanced HER2 breast cancer indicated a good safety of the test drug, and responses to anti-tumor therapy were observed in the target dose group. Phase II clinical trial is being carried out gradually. This trial is designed to observe the effectiveness and safety of pyrotinib maleate combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer patients experiencing a poor efficacy of trastuzumab and pertuzumab.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) — The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.

Primary Outcomes

  • Residual tumor burden (RCB) classification in grades (At least 3 years since enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-08-01
Completion: 2027-08-15
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Principal Investigators:
  • Cai-Gang Liu (PRINCIPAL_INVESTIGATOR) - Department of Breast Surgery, Shengjing Hospital affiliated to China Medical University
Contact Information
Study Contact:
Nan Niu, MD
8618940256668
niunannancy@163.com
Nan Niu, MD
Shengjing Hospital affiliated to China Medical University
Cai-Gang Liu, MD
Shengjing Hospital affiliated to China Medical University
Interventions
  • Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) — The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
Study Locations (1 sites)
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning 110004 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 but ≤ 75 years (The maximal age of the subjects enrolled in the Phase 3 study of pyrotinib is 75 years old, and there is no safety data for the use of the drug in older people); * Diagnosis of breast cancer meets the following criteria: Histologically confirmed invasive breast cancer; Tumor staging: Stage II-III patients who meet the 8th edition of AJCC Cancer Staging Manual; Patients who have undergone neoadjuvant therapy with trastuzumab and pertuzumab and have been assessed as SD (an increase of 0-20%), PD, inoperable or failing to meet the breast-conserving requirements; Failing to meet the breast-conserving requirements is defined as not meeting the following criteria: tumor size of T1 and T2 stage, proper breast volume, proper tumor-to-breast volume ratio, and able to maintain a good breast shape after surgery. * HER2-positive breast cancer pathologically confirmed is defined as Immunohistochemical method (IHC3+) or FISH+; * Eastern Cooperative Oncology Group (ECOG) level 0-1; * The functional level of major organs must conform to the following requirements: Neutrophils (ANC) ≥ 1.5×109/L (with no use of growth factors within 14 days); Platelet count (PLT) ≥ 100×109/L (with no correct treatment within 7 days ); Hemoglobin (Hb) ≥ 90 g/L (with no correct treatment within 7 days ); Total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; Urea nitrogen and creatinine ≤ 1.5×ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); Cardiac color Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥ 50%; 12-lead electrocardiogram: QT interval ≤ 480 ms; * Able to receive needle biopsy; * Patients who participate in the trial voluntarily, sign an informed consent, have good compliance and are willing to comply with the follow-up visit. Exclusion Criteria: * Patients who are concurrently receiving other anti-tumor therapy; * Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer; * With a history of any malignancies other than breast cancer in the past 5 years, excluding cured cervical carcinoma in situ, non-melanoma skin cancer or other malignant tumors; * Inability to swallow, chronic diarrhea and intestinal obstruction, and having many factors that affect drug administration and absorption; * Cardiac insufficiency, including but not limited to congestive heart failure, transmural myocardial infarction, angina pectoris requiring medical treatment, clinically significant valvular disease and high-risk arrhythmia, or abnormal QTc in the ECG examination during the screening period (at rest, QTc \> 450 ms in male or QTc \> 470 ms in female after correction of ECG examination); * Uncontrolled hypertension (at rest, systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg); * Patients who are suffering severe or uncontrolled systemic diseases, such as unstable or uncompensable respiratory, heart, liver, or kidney diseases, as per the investigator's judgments; * Female patients during pregnancy and lactation, or those who are fertile and positive for baseline pregnancy test or those of childbearing age who are unwilling to take effective contraceptive measures throughout the trial period; * Serious concomitant diseases or other comorbid diseases that will endanger the safety of patients or interfere with the completion of the trial, including but not limited to severe hypertension, severe diabetes mellitus, and active infections that are out of control; * Patients with known allergies to any active ingredients or excipients of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; * With a history of interstitial pulmonary disease, drug-induced pulmonary interstitial disease, and radiation pneumonitis that require hormone therapy, or any clinically active pulmonary interstitial disease as suggested by any evidence; * Patients who are currently suffering from keratitis, corneal disease, retinal disease, or active eye infection that require any interventions for the eyes.
Conditions Breast Cancer
Phase PHASE2
Enrollment 80
Locations 34 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Inavolisib — Participants will receive Inavolisib as per the schedule given in the protocol.
  • Drug: Fulvestrant — Participants will receive Fulvestrant as per the schedule given in the protocol.

Primary Outcomes

  • Percentage of Participants With Objective Response Rate (ORR) (Up to approximately 2 years)
  • Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-18
Completion: 2031-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO46063 https://forpatients.roche.com/ No attachments to email below.
888-662-6728
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Inavolisib — Participants will receive Inavolisib as per the schedule given in the protocol.
  • Drug: Fulvestrant — Participants will receive Fulvestrant as per the schedule given in the protocol.
Study Locations (34 sites)
Los Angeles Cancer Network, Los Angeles, California 90017-4803 United States
Cancer Specialists of North Florida, Jacksonville, Florida 32256 United States
HCA Midwest Division, Kansas City, Missouri 64132 United States
Astera Cancer Care East Brunswick, East Brunswick, New Jersey 08816 United States
Instituto de Oncologia de Rosario, Rosario, Santa Fe Province S2000KPG Argentina
Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE Argentina
Hospital Privado - Centro Medico de Córdoba, Córdoba, 5016 Argentina
Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE Argentina
Hospital Provincial del Centenario, Rosario, S2002KDS Argentina
Centro Oncológico de Excelencia, San Juan, J5402BGA Argentina
Eligibility Criteria
Inclusion Criteria: * Documented ER +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 1 prior lines of systemic therapy in the locally advanced (recurrent or progressed) or metastatic setting * Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) * Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines * Confirmation of biomarker eligibility: presence of \>= 1 study-eligible PIK3CA mutation * Life expectancy of \> 6 months * Ability, in the investigator's judgment, and willingness to comply with all study -related procedures, including completion of patient-reported outcomes Exclusion Criteria: * Metaplastic breast cancer * Prior treatment with chemotherapy in the recurrent locally advanced/metastatic setting * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Prior treatment with PI3K/Akt/mTOR inhibitors in the recurrent locally advanced/metastatic setting * Requirement for daily supplemental oxygen * Symptomatic active lung disease, including pneumonitis
Conditions Hormone Receptor Positive HER-2 Negative...
Phase PHASE2
Enrollment 176
Locations 36 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Trial design: Phase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1 randomization into Arm A (olaparib + elacestrant) or arm B (olaparib). Treatment in either arm will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study. Trial population: Patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with an indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib, an ECOG performance status of 0-2 and life expectancy of \> 6 months, with normal bone marrow and kidney functions and no active or newly diagnosed central nervous system (CNS) metastases or symptomatic metastatic visceral disease at risk of life-threatening complications. Interventions: Patients randomized to Arm A will receive 600 mg olaparib daily and 400 mg elacestrant daily, while patients randomized to Arm B will receive 600 mg olaparib daily. Blood tests (hematology, biochemistry) will be performed at the beginning of every cycle, and imaging for tumor assessment (chest and abdominopelvic imaging) as well as QoL assessments will be performed every three months and in case of suspicion of progression/end of study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Olaparib + Elacestrant — Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
  • Drug: Olaparib — Olaparib 600 mg orally daily

Primary Outcomes

  • Progression free survival (PFS) (PFS is defined as the time from randomization to first progression as assessed by the investigator, or death, whichever occurs first, assessed up to 48 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-13
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 176 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GBG Forschungs GmbH
Collaborators: Stemline Therapeutics, Inc.
Principal Investigators:
  • Sibylle Loibl, MD, PhD (STUDY_CHAIR) - Prof., MD ASCO, ESGO, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Faculty Member, SABCS Faculty member
Contact Information
Study Contact:
Laura Steinmann
+49 61027480
element@gbg.de
Stefan Schoeffel
+49 61027480
element@gbg.de
Manfred Hofmann, PD Dr.
manfred.hofmann@vinzenz.de
Vinzenz Von Paul Kliniken gGmbH - Marienhospital
Interventions
  • Drug: Olaparib + Elacestrant — Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
  • Drug: Olaparib — Olaparib 600 mg orally daily
Study Locations (36 sites)
Vinzenz Von Paul Kliniken gGmbH - Marienhospital, Stuttgart, Baden-Wurttemberg Germany
University Hospital Tübingen, Tübingen, Baden-Wurttemberg 72076 Germany
Rems-Murr-Klinik-Winnenden, Winnenden, Baden-Wurttemberg Germany
GRN Klinik Weinheim, Weinheim, Baden-Württembergs 69469 Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH, Augsburg, Bavaria 86150 Germany
Klinikum Bayreuth, Bayreuth, Bavaria Germany
Schwerpunktpraxis der Gynäkologie und Onkologie, Fürstenwalde, Brandenburg 15517 Germany
Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt am Main, Hesse 60431 Germany
Klinikum der J. W. Goethe Universität, Frankfurt am Main, Hesse 60590 Germany
Klinikum Kassel GmbH - Frauenklinik, Kassel, Hesse 34125 Germany
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for study participation only if they comply with the following criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for scheduled visit, the treatment and follow-up, must be obtained and documented according to the local regulatory requirements. 2. Female or male patients. 3. Age at study entry of at least 18 years. 4. Locally advanced or metastatic breast cancer that is HR-positive (ER and/or PgR ≥ 10% of stained cells at IHC) and HER2-negative (IHC 0 or 1+, or 2+ and ISH negative according to ASCO/CAP guidelines). 5. Patients with deleterious or suspected deleterious gBRCA1/2 mutation detected upon local testing. 6. Willingness and ability to provide archived formalin fixed paraffin embedded tissue (FFPE) block or a partial block from archived tumor or metastasis. 7. Indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. 9. Resolution of all acute toxic effects of prior anti-cancer therapy including endocrine therapy or surgical procedures to NCI CTCAE version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). 10. Life-expectancy \> 6 months. 11. For female patients: patients of childbearing potential (defined as not post-menopausal and not permanently sterile \[latter defined as having undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\]) require a negative serum or urinary pregnancy test within 72 hours before starting treatment in this study (in this case, patients need to use highly effective non-hormonal contraceptive methods as specified in the protocol). For male patients: during the intervention period and for at least 120 days after the last dose of elacestrant, patients should refrain from heterosexual intercourse or use a condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak), and they should refrain from donating sperm. Exclusion Criteria: Patients will be ineligible for study participation if they fulfill any of the following criteria: 1. Known hypersensitivity reaction to one of the compounds, excipients, or substances used in this protocol. 2. Active or newly diagnosed CNS metastases, including leptomeningeal carcinomatosis, carcinomatous meningitis, or radiographic signs of CNS hemorrhage. Note: Patients with stable brain metastases are allowed. Radiotherapeutic treatment must be completed 1 week before planned day 1 of study therapy. 3. Presence of symptomatic metastatic visceral disease that are at risk of life-threatening complications in the short term, including but not confined to massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or fulminant liver involvement. 4. Inadequate organ function prior to enrolment including: * Hemoglobin \< 9 g/dL (\< 5.6 mmol/L) * Absolute neutrophil count (ANC) \< 1500/mm³ (\< 1.5 x 109/L) * Platelets \< 100,000/mm³ (\< 100 x 109/L) * Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) \> 3 x upper normal limits (ULN). If the patient has liver metastases, ALT and AST should not be ≥ 5 x ULN. * Alkaline phosphatase (ALP) \> 2.5 x ULN * Total serum bilirubin \> 1.5 x ULN (exception: patients with Gilbert's syndrome permitted up to ≤ 3 x ULN) * Serum creatinine \> 1.5 x ULN or estimated creatinine clearance \< 50 mL/min as calculated using the standard method for the institution. 5. Existing contraindication against the use of the elacestrant or olaparib. 6. Prior treatment with PARP inhibitors. 7. Female patients: pregnancy or lactation at the time of randomization or intention to become pregnant during the study and for a predefined period after the end of treatment (as described in protocol). Male patients: intention to get a child during the study and for a predefined period after the end of treatment (as described in protocol). According to the treatment received during the study, required contraception timelines for female and male patients are described in the study protocol. 8. Any of the following within 6 months prior to enrolment: myocardial infarction, severe/unstable angina, ongoing grade ≥ 2 cardiac dysrhythmias, prolonged QT corrected by Fridericia's formula (QTcF) grade ≥ 2, uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, heart failure of New York Heart Association (NYHA) Class II or greater, or cerebrovascular accident including transient ischemic attack. 9. Uncontrolled hypertension at the time of screening (systolic BP \> 140 mmHg or diastolic BP \> 90 mmHg that has not been adequately treated or controlled). 10. Active and current anticoagulation for treatment purposes of thrombotic events occurring \< 6 months before enrolment is not allowed (prophylactic anticoagulation, however, is acceptable). Treatment with an anticoagulant for a thrombotic event occurring \> 6 months before enrolment, or for an otherwise stable and allowed medical condition (e.g., well controlled atrial fibrillation) is acceptable, provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to the first dose of study drug. 11. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥ grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass. 12. History of endometrial intraepithelial neoplasia in patients who have not undergone a hysterectomy. 13. Malignant disease other than breast cancer, active or being disease-free for less than 5 years (except carcinoma in situ of the cervix, DCIS, and non-melanomatous skin cancer adequately treated). 14. Uncontrolled significant active infections including HBV, HCV, and/or HIV. Patients with a positive hepatitis B surface antigen result or a positive hepatitis C antibody test result at screening or within 3 months before first dose of study treatment are excluded, except for the following: * Participants with positive anti-HBs antibody titer and confirmatory negative hepatitis B DNA polymerase chain reaction. * Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if they have both completed curative therapy and have a hepatitis C viral load \< quantifiable limit. 15. Any severe, acute, uncontrolled, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational or non-investigational products administration, or may interfere with the interpretation of study results, and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. Moreover, patients who, by virtue of an order issued by judicial or administrative authorities, are committed to an institution or those who cannot take part in clinical trials are excluded from this study. 16. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent. 17. Unable or unwilling to avoid medications, supplements (e.g., St. John's wort), or foods (e.g., grapefruit, pomegranate, pomelos, star fruit, Seville oranges and their juices) that are moderate/strong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, or foods are discontinued for at least 14 days prior to study entry and for the duration of the study. 18. Concurrent treatment with other experimental
Conditions Breast Neoplasm Female
Phase PHASE4
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel — Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.

Primary Outcomes

  • Response to Paclitaxel (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2017-03-13
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Marina Sharifi, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Cancer Connect
800-622-8922
clinicaltrials@cancer.wisc.edu
Mark Burkard, MD, PhD
University of Iowa Health Care/Holden Comprehensive Cancer Center
Cancer Connect
800-622-8922
clinicaltrials@cancer.wisc.edu
University of Wisconsin Carbone Cancer Center
Interventions
  • Drug: Paclitaxel — Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
Study Locations (2 sites)
University of Iowa Health Care/Holden Comprehensive Cancer Center, Iowa City, Iowa 52242 United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792 United States
Eligibility Criteria
Inclusion Criteria: * Women with pathologically demonstrated breast cancer * Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist. No other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel. * Patients must not have metastatic disease on staging work-up per institutional guidelines. * A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor (preferred) or lymph node. A minimum of 8 slides must be available. * The primary tumor or lymph node must be readily biopsied by surgery or radiology teams. * The primary tumor must be measurable by an imaging modality prior to treatment. This imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery. Such imaging modalities may include ultrasound, CT, mammography, or MRI. MRI will be the preferred imaging modality if available because it has the highest accuracy and positive predictive value for predicting pathologic complete response.All imaging will be performed per standard of care at the discretion of the treating physicians. * Subjects may not have had prior systemic chemotherapy regimens administered for treatment of their current breast cancer. However, studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted. * Patients must have adequate organ and marrow function as determined by the treating oncologist. * Patient must be willing to undergo additional biopsy of breast tumor or lymph node. * Patient must have the ability and willingness to sign a written informed consent document. * Women of childbearing potential (per institutional policy) must agree to use effective contraception as discussed with treating oncologist for the duration of the study. Exclusion Criteria: * History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in Cremophor(R) EL (polyoxyethylated castor oil). * Patients with known HIV due to concern that chemotherapy may cause further immunosuppression and potential infectious complications. * Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with biopsy. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, other malignancies requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements as determined by treatment physician. * Pregnant women are excluded from this study because paclitaxel is a pregnancy category D drug and may cause deleterious effects to the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial.
Conditions HR+/HER2- Breast Cancer, HR+, HER2-, Adv...
Phase PHASE1, PHASE2
Enrollment 380
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AVZO-021 — AVZO-021 is an oral selective CDK2 inhibitor
  • Drug: Fulvestrant — Antineoplastic agent, estrogen receptor antagonist
  • Drug: Letrozole — Antineoplastic agent, aromatase inhibitor
  • Drug: AVZO-023 — AVZO-023 is an oral selective CDK4 inhibitor

Primary Outcomes

  • Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1) (Cycle 1 (28 Days))
  • Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1) (From baseline until end of study treatment or study completion (approximately 2 years))
  • Determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) (Phase 1) (Approximately 16 months)
  • Objective Response Rate (ORR) (Phase 2) (From baseline through disease progression or study completion (approximately 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-08-20
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Avenzo Therapeutics, Inc.
Contact Information
Study Contact:
Medical Information
(858) 239-2944
ClinicalTrials@avenzotx.com
Avenzo Therapeutics
Avenzo Therapeutics Recruiting Site
Avenzo Therapeutics
Avenzo Therapeutics Recruiting Site
Interventions
  • Drug: AVZO-021 — AVZO-021 is an oral selective CDK2 inhibitor
  • Drug: Fulvestrant — Antineoplastic agent, estrogen receptor antagonist
  • Drug: Letrozole — Antineoplastic agent, aromatase inhibitor
  • Drug: AVZO-023 — AVZO-023 is an oral selective CDK4 inhibitor
Study Locations (16 sites)
Avenzo Therapeutics Recruiting Site, Los Angeles, California 90025 United States
Avenzo Therapeutics Recruiting Site, Los Angeles, California 90095 United States
Avenzo Therapeutics Recruiting Site, New Haven, Connecticut 06519 United States
Avenzo Therapeutics Recruiting Site, Orlando, Florida 32827 United States
Avenzo Therapeutics Recruiting Site, Sarasota, Florida 34232 United States
Avenzo Therapeutics Recruiting Site, Tampa, Florida 33612 United States
Avenzo Therapeutics Recruiting Site, Boston, Massachusetts 02215 United States
Avenzo Therapeutics Recruiting Site, New York, New York 10016 United States
Avenzo Therapeutics Recruiting Site, Cleveland, Ohio 44106 United States
Avenzo Therapeutics Recruiting Site, Columbus, Ohio 43221 United States
Eligibility Criteria
Key Inclusion Criteria: * Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncology Group (ECOG) 0-1 and life expectancy \> 3 months * Patients with histologically or cytologically proven advanced malignancies of preferred indications * Measurable disease (as assessed by investigator using RECIST v1.1) is preferred in Phase 1 dose escalation, unless otherwise specified in the protocol, and in all patients in Phase 2. Bone only disease is allowed in dose escalation. * Agree to provide molecular test report results to confirm eligibility and archival tumor samples and/or fresh biopsy, as applicable * Adequate renal, liver, and bone marrow function Key Exclusion Criteria: * Patients should not have received any prior selective investigational CDK (CDK2, CDK4, CDK2/4, CDK2/4/6) inhibitors * Has known active brain metastasis (have either previously untreated intracranial CNS metastasis or previously treated intracranial central nervous system (CNS) metastasis with radiologically documented new or progressing CNS lesions) or leptomeningeal disease * Other concurrent invasive malignancy or a prior invasive malignancy for which treatment was completed within 3 years before the first dose on study except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or colorectal adenomatous polyps * Last anticancer treatment within 2 weeks (4 weeks for biologic, immunotherapy or ADC) or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * Major surgery within 4 weeks prior to first dose on study * Have received radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have active radiation pneumonitis. Patients who received radiation of \>25% of bone marrow are excluded. * Strong or moderate CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * History of serious cardiovascular conditions within 6 months prior to first dose on study * Unresolved toxicities from prior therapy greater than Grade 1 (per CTCAE version 5.0) (with exceptions of alopecia, vitiligo, and ≤ Grade 2 peripheral neuropathy) prior to the first dose on study * History of drug-induced pneumonitis/interstitial lung disease * Confirmed loss of function mutation or deletion of Rb1 gene * Previous high-dose chemotherapy requiring stem cell rescue

Intra-Operative Radiation Registry

NCT04994067
Recruiting
Conditions Breast Cancer
Phase Not Applicable
Enrollment 460
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable partial breast irradiation (PBI) per the latest American Society of Radiation Oncology (ASTRO) guidelines.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients with locally controlled disease (5 years following radiation therapy)
  • Number of patients with regionally controlled disease (5 years following radiation therapy)
  • Number of patients with grade 2 or higher toxicities (5 years following radiation therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-08-09
Completion: 2032-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 460 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Albert Einstein College of Medicine
Principal Investigators:
  • Jana Fox, MD (PRINCIPAL_INVESTIGATOR) - Montefiore Medical Center
Contact Information
Study Contact:
Jana Fox, MD
718-920-4140
jfox@montefiore.org
Jana Fox
718-920-4140
jfox@montefiore.org
Montefiore Medical Center - Moses Campus
Jana Fox
Montefiore Medical Center - Moses Campus
Interventions
N/A
Study Locations (1 sites)
Montefiore Medical Center - Moses Campus, The Bronx, New York 10467-2490 United States
Eligibility Criteria
Inclusion Criteria: * Female gender * Age ≥ 45 * cT1-2N0, \<3.5cm invasive breast cancer, estrogen-receptor positive or DCIS of breast, Grade 1-2, mammographically detected, \< 2.5 cm, estrogen-receptor positive * Suitable for breast conserving surgery * No contraindication to radiation * Mammogram within 6 months of planned procedure * Fitness for lumpectomy under general anesthesia * Planned to receive IORT Exclusion criteria * Known axillary lymph node positive breast cancer (negative biopsy not required) * Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound, MRI or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy. * Patients known to have BRCA 1/2 (breast cancer 1, breast cancer 2) gene * Patients undergoing neoadjuvant chemotherapy * Pregnancy
Conditions Breast Cancer
Phase PHASE2
Enrollment 100
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Focal Radiation therapy — Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
  • Drug: Pembrolizumab (200mg IV for 30 minutes — Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
  • Biological: CDX-301 — Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.

Primary Outcomes

  • Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm. (3 years)
  • Clinical response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured. (3 years)
  • Pathological response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-03-17
Completion: 2027-12-31
Eligibility
Age: 18 Years – 90 Years
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics
Principal Investigators:
  • Silvia Formenti, M.D. (PRINCIPAL_INVESTIGATOR) - Weill Cornell Medicine - New York Presbyterian Hospital
Contact Information
Study Contact:
Fabiana Gregucci, M.D.
646 962-3110
fgr4002@med.cornell.edu
Sarah Stankiewich
718-661-7246
sas9306@nyp.org
New York Presbyterian Hospital - Queens
Sharanya Chandrasekhar
6469623110
shc2043@med.cornell.edu
New York Presbyterian Hospital - Queens
Interventions
  • Radiation: Focal Radiation therapy — Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
  • Drug: Pembrolizumab (200mg IV for 30 minutes — Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
  • Biological: CDX-301 — Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
Study Locations (8 sites)
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
Icahn School of Medicine at Mt Sinai, New York, New York 10027 United States
New York Presbyterian Hospital - Queens, New York, New York 10065 United States
Weill Cornell Medicine New York Presbyterian Hospital, New York, New York 10065 United States
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York 11215 United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232 United States
UT Southwestern Medical Center, Dallas, Texas 75390-9179 United States
Houston Methodist Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Post-menopausal female ≥ 18 years of age (Post-menopausal status defined as either 1) at least 2 years without menstrual period or 2) or patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Biopsy proven diagnosis of ER+ PR+ or PR- HER2- breast cancer. * Clinical stage I(\>1.5cm, if N0) - III breast cancer, as per AJCC staging 8th edition. * Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document. Adequate bone marrow reserve and liver function: WBC ≥ 2000/uL Absolute neutrophil count (ANC) ≥1500/μL Platelets ≥100 000/μL Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases) International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants Exclusion Criteria: * Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy * Current use of systemic chemotherapy, endoctine therap or HER2-neu targeted therapy * Post surgical excision of breast cancer. * Previous radiotherapy of the same breast. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137). * Inability to obtain histologic proof of breast cancer * Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. * Has a known additional malignancy (second primary) that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. cervical cancer in situ) that have undergone potentially curative therapy are not excluded. * Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * Has an active infection requiring systemic therapy.Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority. * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. * Has a known history of active TB (Bacillus Tuberculosis). Note: optional based on country. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

SL-28 for Advanced Solid Tumours

NCT07341737
Recruiting
Conditions Head & Neck Cancer, Pancreas Carcinoma, ...
Phase PHASE1, PHASE2
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: SL-28 — Doses administered: 3×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
  • Biological: SL-28 — Doses administered: 6×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
  • Biological: SL-28 — Doses administered: to-be-determeined-later Mode of administration: intravenous push

Primary Outcomes

  • Number of participants with treatment-emergent adverse events (12 weeks)
  • To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion. (12 weeks)
  • Change from baseline in ECG QT interval (12 weeks)
  • Change from baseline in vital signs (12 weeks)
  • Change from baseline in vital signs (12 weeks)
  • Change from baseline in vital signs (12 weeks)
  • Number of participants with dose-limiting toxicities (DLTs) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-08-14
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Life Therapeutics
Contact Information
Study Contact:
George Tetz, MD, PhD
16466173088
clinical@secondlifetx.com
Udit Nindra, Dr
+61287389744
Udit.Nindra@health.nsw.gov.au
Liverpool Hospital
David Martin, MD
0755980964
dm.oncology@gmail.com
John Flynn Private Hospital
Interventions
  • Biological: SL-28 — Doses administered: 3×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
  • Biological: SL-28 — Doses administered: 6×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
  • Biological: SL-28 — Doses administered: to-be-determeined-later Mode of administration: intravenous push
Study Locations (3 sites)
Liverpool Hospital, Sydney, New South Wales 3170 Australia
John Flynn Private Hospital, Gold Coast, Queensland 4224 Australia
The Southern Oncology Clinical Research Unit (SOCRU), Adelaide, South Australia 5042 Australia
Eligibility Criteria
Inclusion Criteria: * Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study * Adult males and females ≥18 years of age at screening * Life expectancy of at least 3 months * Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced) * Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular/biomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate * Eligible tumor types include: * Head and neck squamous cell carcinoma * Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer) * Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma) * Genitourinary malignancies (bladder, renal cell, prostate cancer) * Gynecologic malignancies (ovarian, endometrial cancer) * Breast cancer and melanoma * Evaluable disease per RECIST v1.1 * ECOG performance status 0-1 (or up to 2 at PI discretion) * Adequate organ function, defined as: * Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome) * AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion) * Creatinine clearance ≥50 mL/min (Cockcroft-Gault) or eGFR ≥50 mL/min (CKD-EPI) * Absolute neutrophil count ≥1,000/mm³ * Platelet count ≥100,000/mm³ * Hemoglobin ≥90 g/L without transfusion within 2 weeks * Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation) Female patients: -Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose Male patients: * Agreement not to donate sperm for 90 days post-dose * Agreement to use adequate contraception as applicable * Suitable venous access for blood sampling * Willingness and ability to comply with study procedures and protocol requirements Exclusion Criteria: * Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies) * NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG * QTcF \>470 ms (females) or \>450 ms (males) * Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy * Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing * Prior therapies within restricted timeframes: * Immune checkpoint inhibitors or biologics within 28 days * Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days * Unapproved investigational drugs within 5 half-lives * Nitrosoureas or mitomycin C within 6 weeks * Concurrent malignancy within 5 years, except specified low-risk cancers * Pregnancy or breastfeeding * Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection * Inability or unwillingness to comply with protocol procedures * History of anaphylaxis or significant allergy interfering with participation * Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months * Conditions affecting drug absorption, distribution, metabolism, or excretion * Receipt of live vaccines within 28 days prior to screening * Participation in another investigational study within 30 days prior to screening
Conditions Breast Cancer, High Risk of Breast Cance...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perform robotic nipple sparing mastectomy (rNSM) and immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (ADM - Alloderm), for patients with breast cancer as well as those with a high risk for breast cancer. Safety and feasibility measures will be measured as primary outcome measures. Oncological and patient satisfaction outcome measures will be measured. Our hypothesis is that SPr-NSM is equal to open NSM in terms of safety, feasibility and oncological outcomes with improved patient satisfaction as measured by nipple sensation and patient reported outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: da Vinci SP Surgical System — This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.

Primary Outcomes

  • Number of participants who complete single port nipple sparing mastectomy (SPrNSM) (Date of surgery (Day 1))
  • Incidence of perioperative complications (30 days following surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-08
Completion: 2027-02
Eligibility
Age: 18 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Deborah Farr, MD
Principal Investigators:
  • Deborah Farr, MD, FACS (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Deborah Farr, MD, FACS
214-648-4133
Deborah.Farr@UTSouthwestern.edu
Deborah E Farr, MD
UT Southwestern
Interventions
  • Device: da Vinci SP Surgical System — This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
Study Locations (1 sites)
UT Southwestern, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * Candidates for open nipple sparing mastectomy, per standard of care with regards to anatomic factors and tumor location including: nipple sparing resection and resection OR prophylactic mastectomy for risk reduction OR treatment of ductal carcinoma in-situ or clinically node negative cT1-T3 breast cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Inability to provide informed consent * Pregnant or nursing women * Patients with: * Inflammatory breast cancer * Skin involvement with tumor * Pre-operative diagnosis of Nipple Areolar Complex (NAC) tumor involvement * Grade 3 or higher nipple ptosis * Contraindicated for general anesthesia or surgery * Heavy current smoking history (defined as \> 20 cigarettes per day)